Therapeutic advances of maligmant hematological diseases in 2004 of American / 医学研究生学报

ABSTRACT

In the 46th annual meeting of the American Society of Hematology, the advance in the treatment of maligmant hematological disease concentrats on targeted therapies, including oblimersen,combination therapy rituximab with the chemotherapeutic agent, proteasome inhibitor bortezomid, flavorpiridol and radioimmunotherapy. Hematopoietic cell transplantation (HCT) is an effective therapy of maligmant hematological disease. The foremost advantage of the nonmyeloablative or reduced-intensity HCT is the reduction of treatment-related mortality .